Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, Nov. 4, 2021, following the release of its third quarter 2021 financial results.

The call may be accessed by dialing 1-888-437-3179 (domestic) or 1-862-298-0702 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available shortly after completion of the call and will be archived on Puma's website for 90 days.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.


These press releases may also interest you

at 23:00
The popular community supermarket brand Choithrams has been among the first to respond to the oil tanker explosion in Sierra Leone that has made global headlines. The ghastly incident took place in the densely populated Wellington suburb in Sierra...

at 17:08
The Government of Canada has a monitoring program in place with the provinces and territories to identify new COVID-19 variants in Canada, such as the Omicron variant of concern. Genomic sequencing is an integral part of Canada's ongoing response to...

at 17:06
"I was informed today by the Public Health Agency of Canada that testing and monitoring of COVID-19 cases has confirmed two cases of the Omicron variant of concern in Ontario. This development demonstrates that our monitoring system is working. I...

at 10:00
Fovia Ai, Inc., a subsidiary of Fovia, Inc., a world leader in advanced visualization for nearly two decades and a preeminent provider of zero-footprint, cloud-based imaging SDKs, today announced that it will be showcasing visualization, navigation...

at 09:00
November 28, 2021 Robust portfolio of modality and PACS vendor-neutral radiology workflow solutions supports radiologists, technologists and administrators with integrated, automated AI-driven informatics to streamline workflows Smart...

at 09:00
exocad, an Align Technology, Inc. company and a leading dental CAD/CAM software provider, today announced the availability of ChairsideCAD 3.0 Galway in the United States and Canada....



News published on 21 october 2021 at 16:20 and distributed by: